A thumb-sized device made from real patient cells has overturned decades of assumptions about inflammatory bowel disease — and may change how medicine treats it forever.

Scientists at Harvard University and the Wyss Institute for Biologically Inspired Engineering have built a miniature living human colon on a microfluidic chip the size of a USB memory stick – and used it to expose the hidden biological mechanisms that cause Crohn's disease and ulcerative colitis, two of the world's most debilitating and poorly understood digestive disorders. The findings, published in the journal Nature Biomedical Engineering, mark what researchers are calling a fundamental shift in how medicine approaches inflammatory bowel disease, or IBD.

For decades, the underlying forces driving IBD — a condition that causes the immune system to attack the body's own intestinal lining — had resisted clear scientific explanation. The patients endured relentless cycles of pain, bleeding, diarrhoea, and fatigue. Doctors managed symptoms but could not definitively explain the disease's origin or predict its course. Lead researcher Alican Özkan described the problem in stark terms, saying the mechanisms responsible for worsening IBD had remained "a black box" throughout his career.

The chip constructed by his team addresses this issue. Unlike earlier research that depended largely on animal models—mouses, whose gut biology differs significantly from humans— the Harvard device incorporates living cells taken directly from IBD patients. Inside the lab, the chip breathes, stretches and contracts in real time, mimicking the mechanical rhythm of a functioning human intestine during digestion. Researchers were able to simulate blood flow, immune activity, and hormonal changes to observe how diseased tissue actually behaves— something no previous technology had allowed at this level of biological fidelity.

"IBD is a chronic inflammatory disease that is driven by uncontrolled inflammation causing intestinal tissue to lose its integrity."
— Alican Özkan, Lead Researcher, Harvard University / Wyss Institute

Among the study's most significant findings is the role of a cell type that had not previously been identified as a key driver of IBD damage. Fibroblasts—cells whose normal function is to hold tissue together, acting as a kind of biological scaffolding—were observed going rogue in patients with inflammatory bowel disease. Rather than repairing injured intestinal tissue, these abnormal fibroblasts aggressively produced scar tissue, stiffening and progressively destroying the gut wall in a process known as fibrosis. The discovery overturns a longstanding assumption that inflammation alone was the primary cause of intestinal damage and opens an entirely new category of therapeutic targets for drug developers.

The chip also resolved a troubling clinical puzzle that had long frustrated gastroenterologists treating pregnant women with IBD. Women carrying Crohn's disease or ulcerative colitis face significantly elevated risks of miscarriage, premature birth and low birthweight infants and frequently experience severe disease flare-ups during pregnancy. The biological reason for this had remained unclear. When the Harvard team introduced pregnancy hormones into the living colon chips, inflammation and tissue scarring sharply escalated — but only in chips built from IBD patient cells, not in healthy tissue. The specificity of the response confirmed a direct biological link between pregnancy hormones and disease exacerbation in IBD.

"To my knowledge, this is the first model that has recapitulated in vitro the disease exacerbations that pregnant women with IBD often can experience."
— Donald Ingber, Senior Author, Harvard Medical School

The implications extend beyond IBD itself. People living with long-term inflammatory bowel disease carry a meaningfully elevated risk of developing colorectal cancer because decades of chronic inflammation continuously injure intestinal cells in ways that can trigger malignant transformation. Using the chip, scientists observed the earliest microscopic changes associated with cancer formation — cellular alterations that precede tumour development by years. Researchers believe this capability could eventually allow doctors to detect and interrupt cancer progression far earlier than current screening methods permit.

The study was conducted in collaboration with clinicians at McGill University and Massachusetts General Hospital, who supplied matched tissue samples – healthy and diseased colon tissue from the same patients – ensuring that comparisons between normal and IBD-affected guts were biologically precise. This dual-tissue approach was critical to the study's credibility and is expected to be adopted in follow-on research.

Scientists say the technology's most transformative potential lies in personalised medicine. The existing approach to IBD treatment involves considerable trial and error: physicians prescribe one drug, observe the patient's response over weeks or months, and adjust accordingly. Many patients cycle through multiple treatments before finding one that works — if they find one at all. The gut chip could change this calculus entirely. Doctors may one day culture a patient's own intestinal cells onto a chip, test a panel of candidate drugs directly on that patient's living tissue, and select the therapy most likely to succeed before a single dose is administered.

The research arrives after decades in which IBD patients have seen treatments improve incrementally but the disease itself remain biologically opaque. Nearly 1.6 million Americans carry a diagnosis of Crohn's disease or ulcerative colitis, with millions more affected across Europe, South Asia, and the rest of the world. For these patients, the Harvard team's living colon chip represents something that has been in short supply for a long time: a credible, human-biology-based platform to finally understand — and one day outmanoeuvre — the disease that controls their lives.